Story perspectives

New Drug Combo Slashes Advanced Prostate Cancer Progression Risk

10/27/2025

50 4

Summary

Story summary

The experimental drug combination niraparib and abiraterone slowed progression in men with advanced prostate cancer and BRCA mutations, reducing progression risk by about 50% versus standard care.
The phase 3 trial enrolled 696 men across 32 countries and improved radiographic progression-free survival, though serious side effects such as anemia and high blood pressure were more common.
The study emphasizes testing DNA repair gene changes at diagnosis to tailor treatments.

1 of 1

Story summary

The experimental drug combination niraparib and abiraterone slowed progression in men with advanced prostate cancer and BRCA mutations, reducing progression risk by about 50% versus standard care.
The phase 3 trial enrolled 696 men across 32 countries and improved radiographic progression-free survival, though serious side effects such as anemia and high blood pressure were more common.
The study emphasizes testing DNA repair gene changes at diagnosis to tailor treatments.